Podcast

Podcast: This Week in Managed Care—Limiting Surprising Medical Bills and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care stories included the Trump administration looking to bar legal immigrants from using public benefits; a study in The American Journal of Managed Care® finding that a law to limit surprise medical bills is working; data on Affordable Care Act enrollment showing the effect of subsidies.

iTunes

TuneIn

Stitcher

Spotify

Listen above or through one of these podcast services:

Trump Administration Publishes Final Rule Aimed at Legal Immigrants Using Public Benefits

Influence of Out-of-Network Payment Standards on Insurer—Provider Bargaining: California’s Experience

What We're Reading: Ebola Vaccine Victory; ACA Numbers Mixed; Scientists Repurpose Old Drugs

Researchers Say They Developed an Approach to Further Suppress HIV Infection

Evidence-Based Oncology - August 2019

Read more about the stories in this podcast:

Related Videos
Dr Cesar Davila-Chapa
Milind Desai, MD
Masanori Aikawa, MD
James Chambers, PhD
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Screenshot of an interview with Ruben Mesa, MD
Screenshot of Adam Colborn, JD during an interview
Ruben Mesa, MD
Screenshot of Susan Wescott, RPh, MBA
Related Content
A subpopulation of patients with CLL/SLL and secondary immunodeficiency disease carry increased infection risks | image credit: sdecoret - stock.adobe.com
December 19th 2024

Infection Rate More Than Double in CLL/SLL Accompanied By Secondary Immunodeficiency Disease

Karen Jacobson-Sive
Secondary immunodeficiency disease (SID) status was associated with significantly higher risk for severe bacterial infections in adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Managed Care Cast
December 19th 2024

Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma

Giuliana Grossi
Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.
Heart pulse, beat concept in atrial fibrillation | image credit: martialred - stock.adobe.com
December 19th 2024

Q&A: Dr Dan Bloomfield Elaborates on Novel Findings From AZALEA-TIMI 71 Trial, Future of FXI Inhibitor Abelacimab

Kyle Munz
Dan Bloomfield, MD, chief medical officer, Anthos, walks through promising findings demonstrating the efficacy of abelacimab, a factor XI (FXI) inhibitor, to reduce bleeding risk in atrial fibrillation treatment.
Managed Care Cast Presents: Navigating Burdens and Treatment Challenges of IPF
December 12th 2024

Managed Care Cast Presents: Navigating Burdens and Treatment Challenges of IPF

A trio of experts discuss the importance of early diagnosis, treatment barriers, and therapies in the pipeline for idiopathic pulmonary fibrosis (IPF).
Frailty becomes more prevalent in aging populations; however, those affected by MS may exhibit more severe signs of frailty in earlier periods of their life compared to aging groups without MS | image credit: Anastasiia - stock.adobe.com
December 19th 2024

Exploring the Relationship Between MS and Frailty

Karen Jacobson-Sive
The rate of frailty among patients with multiple sclerosis (MS) ranges from 17% to 66% among ambulatory patients, and frailty among MS patients is linked to a host of complications.
Colorectal cancer | Image credit: SewcreamStudio - stock.adobe.com
December 18th 2024

Bevacizumab Biosimilar Equally Effective in Metastatic Colorectal Cancer

Julia Bonavitacola
Compared with originator bevacizumab, the biosimilar version of bevacizumab had equal efficacy when used to treat metastatic colorectal cancer.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo